Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 14,134 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Atopic Dermatitis (AD)
Interventions: Dupilumab, Placebo, Background treatment; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Chicago, Illinois • New York, New York • Dallas, Texas

Conditions: Coronary Heart Disease (CHD)
Interventions: MEDI6570, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 21 Years and older
Enrollment: 423 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 19
States / cities: Mobile, Alabama • Beverly Hills, California • Covina, California + 15 more

Conditions: Dry Eye
Interventions: AXR-159, Vehicle; Drug
Lead sponsor: AxeroVision, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Andover, Massachusetts • Raynham, Massachusetts • Memphis, Tennessee

Conditions: Parkinson Disease
Interventions: CEP-1347 10mg, CEP1347 25mg, CEP-1347 50mg, Placebo Comparator; Drug · Other
Lead sponsor: Cephalon; Industry
Eligibility: 30 Years and older
Enrollment: 806 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 56
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 46 more

Conditions: Malaria
Interventions: D/ChAd63-CA, D/ChAd63-CAT, Infectivity Control (IC) Group; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Bethesda, Maryland • Silver Spring, Maryland

Conditions: Lupus Nephritis
Interventions: BIIB023, Placebo, mycophenolate mofetil, oral corticosteroids; Biological · Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 9
States / cities: Torrance, California • Orlando, Florida • Boston, Massachusetts + 6 more

Conditions: Schizophrenia
Interventions: ABT-126, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 20 Years to 55 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 20
States / cities: Chino, California • Garden Grove, California • National City, California + 17 more

Conditions: Moderate to Severe Osteoarthritis
Interventions: SM04690, 0.03mg/2mL, SM04690, 0.07mg/2mL, SM04690, 0.23mg/2mL, Placebo; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Tucson, Arizona • El Cajon, California • Walnut Creek, California + 4 more

Conditions: Alzheimer Disease
Interventions: ALIA-1758, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: HPV Vaccination, Uptake Vaccination, Series Completion
Interventions: PREVENT; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Psoriasis, Plaque Psoriasis
Interventions: 122-0551, Vehicle; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: San Diego, California • Austin, Texas

Conditions: Heart Failure
Interventions: Placebo, Strata 1 CXL-1020, Strata 2 CXL-1020, Strata 3 CXL-1020; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 15
States / cities: Gainesville, Florida • Jacksonville, Florida • Orlando, Florida + 11 more

Conditions: Chronic Kidney Disease Stage 3
Interventions: AION-301, Placebo; Biological · Drug
Lead sponsor: AION Healthspan, Inc.; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Dermatomyositis
Interventions: JBT-101, Placebo; Drug
Lead sponsor: Corbus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Parkinson Disease
Interventions: RO7486967, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Englewood, Colorado + 6 more

Conditions: Painful Diabetic Neuropathy
Interventions: GRT3938Y, Placebo; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 61
States / cities: Fairhope, Alabama • Homewood, Alabama • Tucson, Arizona + 36 more

Conditions: Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 28
States / cities: Birmingham, Alabama • Sherman Oaks, California • Temecula, California + 21 more

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and atorvastatin, Atorvastatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 78
States / cities: Birmingham, Alabama • Northport, Alabama • Sierra Vista, Arizona + 75 more

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 22
States / cities: Jonesboro, Arkansas • Anaheim, California • Fountain Valley, California + 19 more

Conditions: Acne Vulgaris
Interventions: CB-03-01 cream, 1%, Vehicle cream; Drug
Lead sponsor: Cassiopea SpA; Industry
Eligibility: 9 Years and older
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Sacramento, California + 7 more

Conditions: Partial Epilepsy, Catamenial Epilepsy
Interventions: Ganaxolone, Placebo; Drug · Other
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 27
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more

Conditions: Advanced HER2+Breast Cancer
Interventions: Alpelisib, Alpelisib matching Placebo, Trastuzumab, Pertuzumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Los Angeles, California

Conditions: Impaired Hepatic Function, Healthy
Interventions: ALXN2050; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Hypoparathyroidism
Interventions: MBX 2109, Placebo; Drug · Other
Lead sponsor: MBX Biosciences; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 27
States / cities: Sacramento, California • Jacksonville, Florida • Miami, Florida + 22 more

Search by objective public record fields.

Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction

A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease

Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease

Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults

BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis

A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants

PREVENT Pilot HPV - Related Cancers Trial

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)

Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease.

A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia

An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes

A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)

A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

Study of ALXN2050 in Participants With Hepatic Impairment

Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism